Recommendation for the Management of Spondyloarthritis Patients in Kuwait

This article was published in the following Dove Press journal:
Open Access Rheumatology: Research and Reviews

Objective: In 2016, ASAS and EULAR made joint recommendations for the management of patients with spondyloarthritis. Although Global and European perspectives are important, they cannot accurately reflect the situation for all patients in all countries and regions. As such, the group worked to tailor the existing international recommendations to suit the specific demographic needs of local populations in the Gulf region, with a specific focus on Kuwait.

Methods: Recommendations drafted following a PubMed search for relevant literature were reviewed and then underwent Delphi vote to reach consensus on those to be included. Advice for newly approved agents, including targeted synthetic disease-modifying anti-rheumatic drugs, was included based on the group’s clinical experience.

Results: The resulting 41 recommendations are grouped into five categories covering key definitions and principles for the management and treatment of both axial and peripheral forms of spondyloarthritis.

Conclusion: Through adaptation of existing guidelines and incorporating the current evidence and clinical experience of the members of the group, these recommendations have been developed to reflect the unique situation in Kuwait with regard to differing patient profiles, local culture and approved therapeutic approaches, and are designed to aid in clinical decision-making.

Keywords: spondyloarthropathy, psoriatic arthritis, biological therapy, practice guidelines, ankylosing spondylitis

Introduction

Spondyloarthritis (SpA) is an umbrella term that encompasses several related inflammatory rheumatic conditions and has a heterogeneous presentation. SpA may present in an axial form, predominantly involving the sacroiliac joints and/or the spine, or peripheral form, with arthritis, enthesitis and dactylitis. Axial SpA may be further divided into radiographic axial SpA, with radiographic signs of damage in the sacroiliac joints, or non-radiographic without sacroiliac joint damage. Only recently has it been properly acknowledged that radiographic sacroiliitis is a late finding in the disease course for many patients, and that magnetic resonance imaging (MRI) may show signs of inflammation much earlier than X-ray radiographs show structural damage.

SpA also features extra-articular manifestations, such as inflammatory bowel disease (IBD), anterior uveitis and psoriasis. In the past decade, major progress has been made in the recognition, classification and management of SpA. To provide guidance on the clinical picture of SpA, classification criteria have been...
developed by the Assessment of SpondyloArthritis international Society (ASAS).\textsuperscript{4,5} Also, recommendations on general treatment targets in SpA and the strategy to treat SpA to these targets were developed in 2012 by an international task force.\textsuperscript{6}

In recent years, the rheumatology treatment landscape has benefited from key developments that modulate the inflammatory response through diverse molecular pathways. The successful introduction of tumor necrosis factor (TNF)-blocking therapies in SpA over 15 years ago demonstrated clinical efficacy for axial disease, arthritis and enthesitis, as well as extra-articular manifestations.\textsuperscript{7} While TNF inhibitors (TNFi), categorized as biological disease-modifying anti-rheumatic drugs (bDMARDs), have dramatically improved the treatment and care of SpA patients, there is still a high unmet need for additional therapeutic compounds.\textsuperscript{7} A number of novel treatment strategies have recently yielded promising results in SpA, including non-TNFi bDMARDs, such as interleukin-17 inhibitors (IL-17i), and the introduction of the class of targeted synthetic DMARDs (tsDMARDS), such as Janus kinase inhibitors (JAKi).\textsuperscript{7} The first-in-class JAKi, tofacitinib, has been approved in the US for rheumatoid arthritis (RA) since 2012, and in Kuwait since 2013.\textsuperscript{8} This license has now been extended to include the SpA subtype psoriatic arthritis (PsA) in the US and Europe, and recently in Kuwait.\textsuperscript{9-11}

International Guidelines and Recommendations

In 2017, ASAS and the European League Against Rheumatism (EULAR) jointly published an update of their evidence-based recommendations for the management of people with axial SpA.\textsuperscript{2} Recommendations from the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ARC/SAA/SPARTAN) were also released in the US for ankylosing spondylitis (AS) and non-radiographic axial SpA (nrAxSpA) in 2015.\textsuperscript{12} These recommendations gave guidance on the most frequent and meaningful points related to clinical decision-making in the care of people with AS and nrAxSpA.\textsuperscript{12} Also in 2015, the Canadian Rheumatology Association (CRA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) collaborated to update the recommendations for the management of SpA.\textsuperscript{13}

In North Africa and the Middle East, experts tend to use the ASAS/EULAR recommendations for the management of axial SpA.\textsuperscript{14} The ASAS/EULAR international recommendations state that bDMARDs should be considered in patients with persistently high disease activity despite conventional treatments, with TNFi therapy being the current treatment standard.\textsuperscript{2}

In Kuwait, approved treatments for SpA include non-steroidal anti-inflammatory drugs (NSAIDs) essentially for pain relief, conventional DMARDs (csDMARDs), bDMARDs such as TNFis, and tsDMARDs such as JAKi, for SpA subtypes such as PsA (Table 1). At present, there are no current guidelines available from the Ministry of Health in Kuwait for any class of drugs to treat patients with SpA.

**Why are Regional Considerations Important?**

Global and European perspectives for patient care are essential, but they may not reflect the personal backgrounds and situations of patients in different countries and regions.\textsuperscript{15} For example, for some countries in North

| Class          | Agent                                      |
|----------------|--------------------------------------------|
| NSAIDs         | Celecoxib (Celebrex)                       |
|                | Diclofenac                                 |
|                | Etoricoxib (Arcoxia)                       |
|                | Ibuprofen                                  |
|                | Indomethacin                               |
|                | Meloxicam (Mobic)                          |
|                | Naproxen                                   |
| csDMARDS       | Leflunomide (Arava)                        |
|                | Methotrexate                               |
|                | Sulfasalazine (Salazopyrine)               |
| bDMARDs (TNFi) | Adalimumab (Humira)                        |
|                | Certolizumab pegol (Cimzia)                |
|                | Etanercept (Enbrel)                        |
|                | Golimumab (Simponi)                        |
|                | Infliximab (Remicade)                      |
| bDMARDs (Non-TNFi) | Secukinumab (Cosentyx)               |
|                | Ustekinumab (Stelara)                      |
| tsDMARDs       | Tofacitinib (Xeljanz)                      |
| PDE4i           | Apremilast (Otezla)                        |

**Abbreviations:** NSAIDs, non-steroidal anti-inflammatory drugs; bDMARDs, biological disease-modifying anti-rheumatic drugs; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; PDE4i, phosphodiesterase 4 inhibitor; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitors; tsDMARDs, targeted synthetic disease-modifying anti-rheumatic drugs.
Africa and the Middle East, access to agents to treat SpA and convincing some patients to accept long-term treatment can be challenging. A recent Kuwait registry study demonstrated that accessibility to biologic treatments in Kuwait affects the rate of prescription and the impact on disease activity and quality of life in patients with RA. Management practices vary widely and can be affected by cultural variance, socioeconomics and inadequate local infrastructure, but there is indication that strategies for disease management are evolving in the Middle East, particularly in the Gulf region.

Kuwait, situated at the north eastern edge of the Arabian Peninsula, occupies an area of nearly 18,000 square kilometres and, in 2018, has an estimated population of over 4.2 million, with high expatriate numbers (approximately 70%) and immigration rates. Survey data from Kuwait found that 6.6% of the general population have musculoskeletal pain. This figure increases to 15.7% in people over the age of 50, and 13.5% in people with a body mass index of over 40. Information about the burden of SpA in the North Africa and Middle East region is scarce. Data from Iran give prevalence of 0.23% and 0.12% for SpA and AS, respectively.

Because patient profiles, local considerations and clinical practice in Kuwait may vary from those in Europe or US, a group of experts comprising 14 rheumatologists — including members of the Kuwaiti Association of Rheumatology (KAR) — met in Kuwait City in March 2018, in order to develop adapted recommendations of relevance to local patients. The expert group undertook a modified Delphi process to gain consensus on the applicability of the existing ASAS/EULAR international recommendations for local patients in Kuwait, and to make suggestions for amends and updates. The resulting recommendations are based on the opinions and clinical experience of the authors.

Methods
Delphi Process
PubMed searches using Medical Subject Headings terms for spondyloarthritis, axial spondyloarthritis, psoriatic arthritis and ankylosing spondylitis were made from January 2000 to December 2017 to identify any literature that could inform the development of amended recommendations, including updated guidelines and latest studies in the field. Only articles in the English language and those about patients aged over 18 years were included. Other papers considered relevant could be added by the authors at their discretion.

Thirty-eight drafted recommendations were formulated after the initial searches. In a closed online Delphi exercise, the experts voted on a scale of 0 to 9 to indicate their agreement with each recommendation statement. The calculated means and standard deviations demonstrated that a positive consensus was achieved on 27 recommendations and neutral consensus on the remainder. After discussion and consultation at the March 2018 meeting, 8 recommendations were unchanged and 3 were amended. Also, during the meeting, the expert panel added 4 more recommendations to be considered for the post-meeting Delphi vote. Thus, a final vote incorporated 42 recommendations to reach consensus on. At that time, the experts suggested to combine 2 recommendations into 1, which gives the consensus of 41 recommendations in total that are presented here (Supplement Table 1).

Results
Recommendations
The expert group recommendations are grouped into five categories (Table 2). The first group encompasses the definition of diseases, treatment response and medications, followed by the categories around general management recommendations, and the recommendations for treatment choice, including considerations in special populations (Figure 1).

Definition of Diseases, Treatment Response and Medications
Alongside recommendations, the experts agreed on a standardized definition of diseases, treatment response and medications as stated below.

Definition of Diseases and Treatment Response
1. In axial SpA, a clinical response is defined as an improvement equal or more than 1.1 in AS Disease Activity Score (ASDAS), or an absolute reduction of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) by 2 (0–10 scale), or a relative reduction of 50% within 3 months of treatment initiation.

There are several tools for measuring clinical response to treatment in axial SpA, including the ASAS-defined improvement criteria, BASDAI response criteria, ASDAS improvement criteria and ASDAS disease activity states. The ASDAS improvement criteria define a change in score of at least 1.1 units is equivalent to a “clinically important
### Table 2 Definitions and Recommendations for the Management of SpA in Kuwait

| Topics | Definitions and Recommendations | | Definition of Medication |
|---|---|---|---|
| **Definition of diseases, treatment response and medication** | | | |
| 1. In axial SpA, a clinical response is defined as an improvement equal or more than 1.1 in ASDAS, or an absolute reduction of the BASDAI by 2 (0–10 scale), or a relative reduction of 50% within 3 months of treatment initiation. | | 3. csDMARDs for drugs, such as sulfasalazine, leflunomide and MTX. |
| 2. In peripheral SpA, a clinical response is defined as a reduction in the active joint count of at least 30% within 3 months of treatment initiation. | | 4. bDMARDs for drugs, such as TNFi, IL-17i, and IL-12/23 inhibitors. |
| 5. tsDMARDs for drugs, such as JAK inhibitors and PDE-4 inhibitors. | | |
| **SpA recommendations** | | **Axial SpA recommendations** | **Peripheral SpA recommendations** |
| General principles | 6. The primary goals of managing patients with SpA are control of symptoms and inflammation, prevention of progressive structural damage, and preservation of function. | 9. The treatment of patients with axial SpA should be individualized according to the current signs and symptoms of the disease (axial, peripheral, extra articular manifestations) and patient characteristics, including comorbidities and psychosocial factors. | |
| 7. The treatment strategy for SpA usually requires a multidisciplinary team coordinated by a rheumatologist. | | | |
| 8. Disease monitoring of patients with SpA should include patient-reported outcomes, clinical findings, laboratory tests and imaging, if needed. | | | |
| Non-pharmacological treatment | 10. Treatment of a SpA patient should include education, exercise and physical therapy. | 12. We recommend active physical therapy interventions (supervised exercise) over passive physical therapy interventions (massage, ultrasound, heat) in the treatment of axial SpA. | |
| | 11. We recommend smoking cessation or reduction for a patient with SpA. | | |

(Continued)
### Table 2 (Continued).

| Topics                      | Definitions and Recommendations                                                                 |
|-----------------------------|-----------------------------------------------------------------------------------------------|
|                             | **Definition of Diseases and Treatment Response**                                                 | **Definition of Medication**                                                                 |
|                             |                                                                                               |                                                                                               |
| Pharmacological treatment:  |                                                                                               |                                                                                               |
| NSAIDs                      | 13. We do not recommend a specific NSAID as the preferred choice.                                | 16. NSAIDs can be used for symptomatic patients with axial SpA. An appropriate trial consists  |
|                             |                                                                                               | of at least one NSAID, administered over a minimum of 2 weeks at a maximum tolerated dosage,   |
|                             |                                                                                               | unless contraindicated.                                                                        |
|                             | 14. We conditionally recommend continuous treatment over on-demand treatment with NSAIDs. The  |
|                             | individual risk profile of each patient should be assessed where appropriate and indicated,   |
|                             | considering also the individual patient profile.                                               |                                                                                               |
|                             | 15. When there is no therapeutic advantage of a traditional NSAID, selective COX-2 inhibitor   |
|                             | therapy should be used in patients at an increased risk for GI adverse events. In at-risk       |
|                             | patients who respond best to a traditional NSAID, a gastroprotective agent should be used.      |                                                                                               |
| Pharmacological treatment:  |                                                                                               |                                                                                               |
| Corticosteroids             | 17. Consider corticosteroid injections at the inflammation sites, including sacroiliac joints,  |
|                             | peripheral joints and entheses.                                                                | 19. In adults with active axial SpA, we strongly recommend against long-term treatment with     |
|                             |                                                                                               | systemic glucocorticoids. However, there might be situations where systemic glucocorticoids are  |
|                             |                                                                                               | the only treatment option available.                                                          |
|                             | 18. Consider a short course of systemic corticosteroids for specific manifestations of SpA, such |
|                             | as active peripheral arthritis.                                                                |                                                                                               |
| Topics | Definitions and Recommendations |
|--------|---------------------------------|
| **Pharmacological treatment: csDMARDs** |  |
| | 20. Do not use csDMARDs in the treatment of axial SpA. |
| | 21. csDMARDs can be used in the treatment of patients with chronic peripheral SpA. |
| | 22. Consider combination therapy with csDMARDs in peripheral SpA, particularly in patients with poor prognostic factors, greater disease activity, recent-onset disease and monotherapy resistance. |
| **Pharmacological treatment: bDMARDs and tsDMARDs** |  |
| | 23. bDMARDs and tsDMARDs (according to the local approved indications) should be given only under supervision by a trained physician with experience in monitoring such treatments. |
| | 32. bDMARDs should be offered to patients who show signs of active axial SpA, defined by at least two of the following: BASDAI >4, elevated CRP or ESR, inflammatory lesions in the sacroiliac joints and/or spine on MRI. |
| | 33. In patients with peripheral arthritis (eg, PsA) and an inadequate response to at least one csDMARD, a bDMARD or csDMARDs (according to the local approved indications) should be considered. |
| | 24. Several TNFi are available for the treatment of SpA, including infliximab, etanercept, adalimumab, golimumab and certolizumab. The choice of TNFi should be determined during a consultation between the physician and patient. |
| | 25. The choice of TNFi should incorporate the presence or absence of extra-articular manifestations. |
| | 26. We do not recommend a specific TNFi as the preferred choice, except for patients with concomitant IBD or recurrent uveitis, we recommend monoclonal TNFi. |

*(Continued)*
### Definitions and Recommendations

| Topics | # | Definition of Diseases and Treatment Response | # | Definition of Medication |
|--------|---|-----------------------------------------------|---|--------------------------|
|        | 27. | The decision to maintain a patient on bDMARDs or tsDMARDs should be based on achieving clinical response at least 3 months after initiating treatment. | | |
|        | 28. | Non-responders to TNFi may benefit from switching to another TNFi, IL-17i, IL-12/23i or tsDMARD therapy. | | |
|        | 29. | Consider a monoclonal antibody against IL-12/23 or IL-17i for SpA patients with concomitant moderate-to-severe psoriasis. | | |
|        | 30. | In patients with active enthesitis and/or dactylitis and insufficient response to NSAIDs or local glucocorticoid injections, therapy with a bDMARD should be considered. | | |
|        | 31. | For patients with refractory enthesitis or dactylitis, bDMARDs or tsDMARDs should be considered. | | |
|        | 32. | Prior to initiating therapy with csDMARDs, bDMARDs or tsDMARDs, we recommend testing for hepatitis B and C virus infections, and screening for TB either by tuberculin skin test or interferon release assay. A chest X-ray should be done as an initial test in all patients with SpA, regardless of patient risk factors for latent TB. | | |
|        | 33. | In adults with axial SpA and recurrent uveitis or iritis, we recommend management is coordinated with an ophthalmologist. | | |
|        | 34. | We recommend a pre-evaluation of the TB exposure risk in sero-negative patients receiving bDMARDs or JAKi in whom TB exposure is likely. | | |
|        | 35. | Following the initiation of csDMARDs, or when the dose of these drugs is significantly increased, complete blood counts, liver function tests and serum creatinine should be measured, within appropriate intervals. | | |
|        | 36. | In adults with active non-radiographic axial SpA despite treatment with NSAIDs, we recommend treatment with bDMARDs | | |
|        | 37. | In adults with AS and recurrent iritis, we conditionally recommend treatment with infliximab or adalimumab over treatment with etanercept to decrease recurrences of iritis. | | |

**Special populations**

| # | | |
|---|---|---|
| 39. | In adults with axial SpA and recurrent uveitis or iritis, we recommend management is coordinated with an ophthalmologist. | |
| 40. | In adults with active non-radiographic axial SpA despite treatment with NSAIDs, we recommend treatment with bDMARDs | |
| 41. | When managing patients with PsA, extra-articular manifestations, metabolic syndrome, and cardiovascular disease should be taken into account. | |

(Continued)
improvement”, and a change of at least 2.0 units is considered as “major improvement”.22 Any ASDAS score less than 1.3 is defined as inactive disease.22

2. In peripheral SpA, a clinical response is defined as a reduction in the active joint count of at least 30% within 3 months of treatment initiation.

Once treatment is started, the SpA patient should be monitored to investigate if the target is obtained.2 While in principle the ultimate goal is to achieve an inactive disease state, this may be unreasonable depending on disease phase and previous treatments.2

Definition of Medication

3. csDMARDs for drugs such as sulfasalazine, leflunomide and methotrexate (MTX).
4. bDMARDs for drugs such as TNFi, IL-17i, and IL-12/23 inhibitors.
5. tsDMARDs for drugs such as JAKi and PDE-4 inhibitors.

General Principles

SpA Recommendations

6. The primary goals of managing patients with SpA are control of symptoms and inflammation, prevention of progressive structural damage, and preservation of function.

This recommendation was an amendment of the ASAS/EULAR recommendation for axial SpA.2 SpA is an inflammatory disease; as such, pharmacological suppression of inflammation may be needed in order to relieve symptoms and preserve physical function.2 The 2014 recommendations of an international task force endorsed a treat-to-target approach for SpA6 and were updated in 2017.23 The treatment target for SpA was defined as remission or low disease activity.6,23 The optimal management of patients with SpA requires a combination of non-pharmacological and pharmacological approaches.2 In order to measure the efficacy of a management strategy, it is important to have a measure of clinical response.

There is evidence to support a treat-to-target approach in SpA.23–25 Disease activity has been found to contribute longitudinally to radiographic progression in the spine of patients with AS24 and, used early in the disease, therapeutic interventions that target systemic inflammation may effectively modify the disease course.25

7. The treatment strategy for SpA usually requires a multidisciplinary team coordinated by a rheumatologist.

SpA disorders do not exclusively involve musculoskeletal inflammatory disease but also systemic disease, with clinical features occurring at sites other than the axial skeleton and peripheral joints.26 Extra-articular manifestations in SpA are common, estimated to occur in 50% of patients.27 Extra-articular manifestations may affect the eyes, skin or bowels, triggering uveitis, psoriasis, and inflammatory colitis, respectively.26,27 Patients with SpA may also suffer from other less common manifestations such as cardiovascular or pulmonary complications.26 These manifestations can occur at any time during the disease course, or be the presenting SpA symptom in 20–60% of patients.2,27 Uveitis occurs in 25–40% of patients with SpA;27 psoriasis was found to be present in 32.4%, 82.7% and 1.5% of SpA, PsA and AS patients, respectively;28 and 5–10% of SpA patients will also have IBD.26

Because of the diverse manifestations of SpA, a multidisciplinary approach is often needed. Each area of Kuwait has primary-care polyclinics, and patients seen in primary care are referred to specialist rheumatology clinics. Referrals to rheumatology clinics may also come from
other speciality clinics such as dermatology, gastroenterology, ophthalmology, or internal medicine clinics. On the other hand, the rheumatologist may refer patients with SpA to ophthalmology, gastroenterology or dermatology clinics to treat specific extra-articular manifestations. Clinics usually cooperate in sharing the patient’s full file.

We believe that the rheumatologist is best placed to coordinate other specialties and should retain overall management of the patient, especially if the patient is prescribed bDMARDs or tsDMARDs, which may require additional monitoring. Such coordination in rheumatology can be facilitated by the treating rheumatologist possessing extensive knowledge of the entire SpA spectrum of disease.²

8. Disease monitoring of patients with SpA should include patient-reported outcomes, clinical findings, laboratory tests and imaging, if needed.

This recommendation is amended from the ASAS/EULAR recommendation for axial SpA.²
Figure 1 Recommendations for the management of spondyloarthritis patients in Kuwait. *Consider if the patient has concomitant moderate to severe psoriasis. †Poor prognostic factors include five or more tender or swollen joints; radiographic joint destruction, especially if there is inflammation; elevated acute phase reactants (serum values of inflammatory indicators above the upper limit of normal); and extra-articular manifestations, particularly dactylitis. ‡Consider if the patient has concomitant inflammatory bowel disease or uveitis.

Abbreviations: AE, adverse event; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; csDMARD, conventional systemic disease-modifying antirheumatic drug; GI, gastrointestinal; IL, interleukin; NSAID, nonsteroidal anti-inflammatory drug; PDE4i, phosphodiesterase 4 inhibitor; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.
Due to the heterogeneity of SpA clinical features, patient monitoring should be at the heart of clinical practice using a broad range of assessments tools and following the ASAS core set, as well as other more recent relevant measures such as the ASDAS. The ASAS core set covers symptom-modifying anti-rheumatic drugs and physiotherapy, clinical record keeping, and disease-controlling anti-rheumatic treatment, with level and frequency of monitoring based on disease severity and treatment. Monitoring in clinical practice will depend on the available resources to perform such regulatory requirements.

Individual patient-reported outcomes alone may result in high variability, but are essential to monitor a patient’s pain. Serum C-reactive protein (CRP) levels predict syndesmophyte progression, which in turn correlates with functional impairment; regular laboratory tests can therefore be useful in monitoring. There is also a relationship between disease activity and radiographic progression, which can be monitored using non-invasive imaging techniques. The current practice in Kuwait is to use X-ray and MRI to provide information on inflammation in SpA.

Axial SpA Recommendations
9. The treatment of patients with axial SpA should be individualized according to the current signs and symptoms of the disease (axial, peripheral, extra-articular manifestations), and patient characteristics, including comorbidities and psychosocial factors.

SpA is a heterogeneous disease, indicating the importance of personalized patient management. Both patient fluctuations over time and heterogeneity, respectively, are found at the individual patient level in clinical practice. As such, rheumatologists should consider that not all available treatments may be effective in all disease domains in each patient.

Non-Pharmacological Treatment SpA Recommendations
10. Treatment of a SpA patient should include education, exercise and physical therapy.

This recommendation is amended from the ASAS/EULAR recommendation for axial SpA. Every patient should receive education to help them understand their disease and make informed decisions about their treatment. Non-pharmacological approaches can be used in mild cases, and as an adjunct to support pharmacological treatment in moderate-to-severe disease. Patients should be encouraged to take appropriate exercise to help strengthen their joints and to keep them mobile. Physical therapy may be beneficial and thus advised in some cases. Physical therapy is supported by the Ministry of Health in Kuwait, and also widely available in private practice.

11. We recommend smoking cessation or reduction for a patient with SpA.

In Kuwait, 39% of adult men and 3% of adult women are smokers. Smoking is an important public health concern and increases the disease burden in SpA. There is an association between smoking and radiographic progression, disease activity, inflammation and syndesmophyte formation. Smoking is a modifiable lifestyle factor. Smoking cessation has a potential benefit for patients with axial SpA over those for the general population and should be recommended to all patients.

Axial SpA Recommendations
12. We recommend active physical therapy interventions (supervised exercise) over passive physical therapy interventions (massage, ultrasound, heat) in the treatment of axial SpA.

The optimal management of axial SpA requires a combination of both non-pharmacological and pharmacological approaches. Both active and passive physical therapy options are available in Kuwait. Physiotherapy is considered to play a role in patient management as it helps to maintain function and an adequate quality of life. Tailored to the individual patient, regular physical activity and interruption of sedentary occupations should be encouraged to promote general health and well-being and improve function. Passive physical therapy, such as massage, ultrasound or the application of heat, may help to alleviate symptoms of axial SpA such as pain and stiffness. However, it should be used as an adjunct to regular physical activity, as some forms of deep tissue massage and spinal manipulation can cause disease flares in people with axial SpA and should therefore be avoided.

Our preference is to recommend active physical therapy and supervised exercise programmes, which may help to improve mobility, strength, balance and cardio-respiratory function. Exercise programmes should take into consideration the individual’s physical changes, particularly for those with more severe or later disease. Most types of exercise are safe for the majority of patients, although some high-impact sports and activities (eg, contact sports) may be contraindicated in people with advanced disease.

Individual exercise programmes should place an emphasis
on spinal mobility, although maintaining peripheral joint mobility is also important.42

Pharmacological Treatment

NSAIDs

SpA Recommendations

13. NSAIDs are considered to be first-line therapy for patients with axial SpA without any preferred choice.

NSAIDs are considered to be first-line therapy for patients with axial SpA.44 Most patients with axial SpA show improvement after the recommended 4 weeks of NSAID therapy, although for many patients the disease is still active.44 The inflammatory nature of SpA results in the characteristic signs and symptoms of inflammation and leads to functional impairment and structural changes.6 Arresting inflammation is therefore essential to improve patient outcomes, and use of NSAIDs can alleviate signs and symptoms, improve physical function, and potentially inhibit structural spinal damage.6 There is evidence that continuous NSAID use in patients with an elevated CRP can reduce radiographic progression in AS,45,46 although the evidence is equivocal2 and they do not improve levels of acute phase reactants, suggesting no abrogation of the underlying inflammation.44

NSAIDs available in Kuwait for the treatment of SpA are listed in Table 1. We do not recommend one specific NSAID as the preferred choice; physicians should exercise their judgement to optimize safety and efficacy in line with individual patient factors.

14. We conditionally recommend continuous treatment over on-demand treatment with NSAIDs. The individual risk profile of each patient should be assessed where appropriate and indicated, considering also the individual patient profile.

Compared to on-demand use only, continuous use of NSAIDs may reduce progression of structural damage in the spine.2,45,46 However, both strategies appear to have a similar effect on inflammatory signs and symptoms.45 NSAIDs should be maintained at the maximum tolerated dose for 2 weeks and then tapered to the lowest effective dose while retaining clinical response.

15. When there is no therapeutic advantage of a traditional NSAID, selective COX-2 inhibitor therapy should be used in patients at an increased risk for gastrointestinal (GI) adverse events. In at-risk patients who respond best to a traditional NSAID, a gastroprotective agent should be used.

The potential side-effects of NSAIDs must be considered for each patient before treatment, with continuous risk-benefit assessment during treatment.2 In general, traditional non-selective NSAIDs are associated with GI adverse events, while the more GI-sparing selective cyclooxygenase-2 inhibitors (COX-2i) are associated with a reduction in GI risk in most patients who do not take aspirin concomitantly.47 Evidence suggests that the risk reduction for GI adverse events with COX-2i is approximately equivalent to that achieved by co-prescribing a proton-pump inhibitor with traditional NSAIDs.47 However, COX-2i are not superior to traditional NSAIDs, and individual drugs in the NSAID class (including COX-2i) vary in their ability to potentiate cardiovascular effects.47

Axial SpA Recommendations

16. NSAIDs can be used for symptomatic patients with axial SpA. An appropriate trial consists of at least one NSAID, administered over a minimum of 2 weeks at a maximum tolerated dosage, unless contraindicated.

Risks and benefits of NSAID therapy should be considered on a case-by-case basis. In contrast to the potential safety issues associated with NSAIDs, there may also be risks associated with not using NSAIDs.2 We recommend to use NSAIDs in symptomatic patients only.2 A trial of the NSAIDs should be given at the maximum tolerated dosage.2 If the initiating NSAID elicits a clinical response, then it should be tapered to the lowest dose that maintains the clinical response. However, in cases of treatment failure after administering for at least 2 weeks, rheumatologists have the option to try a different NSAID agent.

Corticosteroids

SpA Recommendations

17. Consider corticosteroid injections at the inflammation sites, including sacroiliac joints, peripheral joints and entheses.

Local injections of glucocorticoid into the site of musculoskeletal inflammation may be an option to treat arthritis and enthesitis in SpA patients.2

18. Consider a short course of systemic corticosteroids for specific manifestations of SpA, such as active peripheral arthritis.

Systemic steroid treatment should not be continued in the long-term because they are associated with serious adverse events and reduction in quality of life.48

Axial SpA Recommendations

19. In adults with active axial SpA, we strongly recommend against long-term treatment with systemic
glucocorticoids. However, there might be situations where systemic glucocorticoids are the only treatment option available.

This recommendation is amended from the ASAS/EULAR recommendation for axial SpA. The ASAS/EULAR task force suggest that patients with axial SpA should not receive long-term treatment with systemic glucocorticoids at any dose. Short-term high-dose courses of glucocorticoids (<50 mg/day) may achieve a modest improvement in the signs and symptoms of axial SpA.

**csDMARDs**

**Axial SpA Recommendations**

20. Do not use csDMARDs in the treatment of axial SpA. csDMARDs available in Kuwait for the treatment of axial SpA are MTX, lefunomide and sulfasalazine (Table 1). However, these disease-modifying therapies may not be effective in treating axial symptoms.

**Peripheral SpA Recommendations**

21. csDMARDs can be used in the treatment of patients with chronic peripheral SpA.

Sulfasalazine may be a treatment option in patients with peripheral arthritis.

22. Consider combination therapy with csDMARDs in peripheral SpA, particularly in patients with poor prognostic factors, greater disease activity, recent-onset disease and monotherapy resistance.

There is limited evidence on the efficacy of combinations of csDMARDs, which focus on peripheral arthritis and PsA. However, csDMARDs may be suitable for patients with peripheral arthritis, especially people with early disease, or with a poor prognosis. Poor prognostic factors include five or more tender or swollen joints; radiographic joint destruction (especially if there is inflammation); elevated acute phase reactants (serum values of inflammatory indicators above the upper limit of normal); and extra-articular manifestations, particularly dactylitis.

**bDMARDs and tsDMARDS**

**SpA Recommendations**

23. bDMARDs and tsDMARDs (according to the local approved indications) should be given only under supervision by a trained physician with experience in monitoring such treatments.

Advanced therapies available in Kuwait for the treatment of SpA are listed in Table 1. bDMARDs should be considered in patients with persistently high disease activity following treatment with conventional therapies, including non-pharmacological management and NSAIDs. bDMARDs have been shown to be effective in improving signs and symptoms and reducing spinal inflammation. Achieving early treatment response with bDMARDs is predictive of better long-term treatment outcomes, with high rates of partial remission or low disease activity. Available data on tsDMARDS indicates their effectiveness as a treatment option for axSpA. However, the risk–benefit of treatment must be assessed by a specialist with experience in the use of bDMARDs or tsDMARDs on an individual case-by-case basis, and both bDMARDs and tsDMARDs require continued monitoring for adverse events.

24. Several TNFi are available for the treatment of SpA, including infliximab, etanercept, adalimumab, golimumab and certolizumab. The choice of TNFi should be determined during a consultation between the physician and patient.

TNFi therapies available in Kuwait for the treatment of SpA are listed in Table 1. The evidence for the use of TNFi in the treatment of SpA is very high, and they can provide sustained long-term efficacy. Overall, all TNFi have proven efficacy in AS and SpA. Large treatment effects have been reported for both radiographic and non-radiographic axial SpA for all TNFi. TNFi also show beneficial effects on extra-articular manifestations. Additionally, treatment with a second TNFi can be effective in cases of treatment failure with the first TNFi.

25. The choice of TNFi should incorporate the presence or absence of extra-articular manifestations.

Not all TNFi appear to be effective in all disease domains and, as noted in the 2016 update of the ASAS-EULAR management recommendations for axSpA, differences in efficacy exist regarding the effect on extra-articular manifestations between the TNFi.

26. We do not recommend a specific TNFi as the preferred choice, except for patients with concomitant IBD or recurrent uveitis, we recommend monoclonal TNFi.

The beneficial effects of TNFi treatment in patients with SpA extend to extra-articular manifestations including uveitis and IBD. A meta-analysis of TNFi demonstrated their efficacy in preventing uveitis flares or new onset of uveitis in AS patients. For patients with uveitis, the monoclonal antibodies adalimumab, certolizumab pegol, golimumab or infliximab are effective therapies. These monoclonal antibodies are also efficacious in the treatment of IBD.

27. The decision to maintain a patient on bDMARDs or tsDMARDs should be based on achieving clinical response at least 3 months after initiating treatment.
There is evidence to suggest advantages of targeting disease activity due to the formation of new syndesmophytes in patients with axial SpA with active disease. Treat-to-target strategies with DMARDs in the rheumatic diseases aim for clinical response at 3 months. If patients are non-responders to treatment at this point, they should be switched to another therapy. Achieving early treatment responses and controlling disease activity leads to better long-term outcomes. Disease activity has been shown to have an effect on radiographic damage and to be significantly associated with radiographic progression in the spine of patients with AS over time.

28. Non-responders to TNFi may benefit from switching to another TNFi, IL-17i, IL-12/23i therapy or tsDMARD.

This recommendation is amended from the ASAS/EULAR recommendation for axial SpA. There is a potential choice of treatment after failure with the first TNFi; patients may switch to an alternative TNFi or to a bDMARD with an alternative mode of action, such as interleukin inhibitors.

29. Consider a monoclonal antibody against IL-12/23 or IL-17i for SpA patients with concomitant moderate-to-severe psoriasis.

The cytokines IL-17, IL-12, and IL-23 play a crucial role in the pathogenesis of psoriasis and the IL-17i secukinumab and IL-12/23 monoclonal antibodies have proven efficacy in psoriasis. To date, trial data on IL-17i are available in radiographic axial SpA.

30. In patients with active enthesitis and/or dactylitis and insufficient response to NSAIDs or local glucocorticoid injections, therapy with a bDMARD should be considered.

Primary characteristics of SpA include enthesitis and dactylitis. Clinical studies in patients with AS have demonstrated the efficacy of TNFi in treating enthesitis. bDMARDs should be considered for patients with refractory enthesitis or dactylitis. TNFi have been shown to deliver high levels of response, and to have good drug adherence in patients with axial SpA.

31. For patients with refractory enthesitis or dactylitis, bDMARDs or tsDMARDs should be considered.

Enthesitis and dactylitis are primary characteristics of SpA. Clinical studies have demonstrated the efficacy of TNFi in treating enthesitis in patients with AS.

Axial SpA Recommendations

32. bDMARDs should be offered to patients who show signs of active axial SpA, defined by at least two of the following: BASDAI >4, elevated CRP or erythrocyte sedimentation rate (ESR), inflammatory lesions in the sacroiliac joints and/or spine on MRI.

TNFi are approved for patients with radiographic axial SpA without further limitations, and in patients with non-radiographic axial SpA only when their CRP is elevated and/or when signs of inflammation are found on MRI. However, there is evidence that patients with radiographic axSpA who also have an elevated CRP have an increased chance of treatment success, and that radiographic sacroiliitis alone is not a predictor of response. In both patients with radiographic and non-radiographic axial SpA, predictors of a good response to TNFi are considered to be firstly elevated CRP and secondly inflammation on MRI. Therefore, there is suggestion that these factors should also be considered when initiating bDMARD therapy regardless of the presence of radiographic sacroiliitis. Also, a recent Phase II placebo-controlled dose-ranging study demonstrated the efficacy and safety of a JAKi, tofacitinib, in reducing signs and symptoms of adults with active AS.

Peripheral SpA Recommendations

33. In patients with peripheral arthritis (eg PsA) and an inadequate response to at least one csDMARD, a bDMARD or tsDMARD (according to the local approved indications) should be considered.

Patients with peripheral arthritis who have an inadequate response to at least one csDMARD should be started on bDMARD therapy. A tsDMARD may also be considered, including in patients in whom bDMARDs are inappropriate, such as those with comorbidities or an infection history contraindicating bDMARDs.

Special Populations

SpA Recommendations

34. Prior to initiating therapy with csDMARDs, bDMARDs or tsDMARDs, we recommend testing for hepatitis B and C virus infections, and screening for tuberculosis (TB) either by tuberculin skin test or interferon-release assay. A chest X-ray should be done as an initial test in all patients with SpA, regardless of patient risk factors for latent TB.

Hepatitis B virus and TB may be reactivated during anti-rheumatic therapy. All SpA patients considered for a treatment with csDMARDs, bDMARDs or tsDMARDs should receive screening for HBV infection, followed by antiviral prophylaxis with oral nucleoside analogue as appropriate. A chest X-ray should be done as an initial test for latent TB in all patients with SpA. Chest radiography prior to initiating treatment is
required because of the high importance of excluding active TB disease and latent TB infection. Testing for latent TB infection before initiating TNFi is advised due to the increased risk of progression to active TB disease.\textsuperscript{71}

35. We recommend a pre-evaluation of the TB exposure risk in sero-negative patients receiving bDMARDs or JAKi in whom the TB exposure is likely.

The majority of people infected with TB have no signs or symptoms of disease, although they are at risk for developing active TB disease depending on their immunological status.\textsuperscript{71} In sero-negative patients in whom TB exposure is likely, risk evaluation is recommended before treating with bDMARDs or JAKi.

36. Following the initiation of csDMARDs, or when the dose of these drugs is significantly increased, complete blood counts, liver function tests and serum creatinine should be measured, within appropriate intervals.

Recommended blood monitoring strategies for DMARDs include assessments of full blood counts, creatinine or estimated glomerular filtration rate, alanine aminotransferase and/or aspartate aminotransferase, and albumin.\textsuperscript{72} These assessments are recommended at treatment initiation and every 2 weeks thereafter until the dose has been stable for 6 weeks; once the dose is stable, every month for 3 months; and thereafter, every 12 weeks.\textsuperscript{72} In cases of dose increases, these assessments should be carried out every 2 weeks until the dose has been stable for 6 weeks; then every month for 3 months; and thereafter, every 12 weeks.\textsuperscript{72} Patients at high risk of toxicity should be monitored more frequently.\textsuperscript{72}

37. In adults with AS and recurrent iritis, we conditionally recommend treatment with infliximab or adalimumab over treatment with etanercept to decrease recurrences of iritis.

While the evidence is inadequate to support a recommendation for use of any particular TNFi over another in patients with AS, the preferred choice of TNFi for patients with AS and recurrent iritis is infliximab or adalimumab over etanercept.\textsuperscript{12}

38. In patients with AS and IBD, we strongly recommend treatment with TNFi monoclonal antibodies over treatment with etanercept.

IBD is associated with AS and axial SpA.\textsuperscript{73} In patients with AS and IBD, the recommended treatment is with TNFi monoclonal antibodies over treatment with etanercept.\textsuperscript{2,12} Trials have demonstrated the efficacy of TNFi monoclonal antibodies, including infliximab, adalimumab, certolizumab, and golimumab, but inefficacy of the fusion protein etanercept in treating IBD.\textsuperscript{2,12} Available evidence has indicated patients are at lower risks of either flare or new onset of IBD with infliximab or adalimumab than with etanercept.\textsuperscript{12}

Axial SpA Recommendations

39. In adults with axial SpA and recurrent uveitis or iritis, we recommend management is coordinated with an ophthalmologist.

Patients with axial SpA have an increased risk of uveitis.\textsuperscript{74} Rheumatologists should be alerted to a disease flare and or inadequate treatment when observing cases of acute anterior uveitis in patients with axial SpA. Ophthalmologists should consider SpA as a possible differential diagnosis in cases of acute anterior uveitis.\textsuperscript{74} Ophthalmologists are best placed for monitoring and manage uveitis or iritis under treatment.

40. In adults with active non-radiographic axial SpA despite treatment with NSAIDs, we recommend treatment with bDMARDs.

This recommendation is in line with ARC/SAA/SPARTAN recommendations for patients with non-radiographic axial SpA whose disease is active and not responding to NSAIDs.\textsuperscript{12} They particularly recommend TNFi in those patients with sacroiliitis on MRI and/or a raised CRP level.

Peripheral SpA Recommendations

41. When managing patients with PsA, extra-articular manifestations, metabolic syndrome, and cardiovascular disease should be taken into account.

PsA is associated with a number of extra-articular manifestations and comorbidities.\textsuperscript{75–77} A number of studies have suggested that patients with psoriatic disease have an increased risk of vascular inflammation, atherosclerotic conditions, myocardial infarction, and stroke, independent of traditional risk factors for cardiovascular disease.\textsuperscript{78–82} Additionally, an increased prevalence of metabolic syndrome has been observed in PsA, over and above that in other inflammatory arthropathies.\textsuperscript{78,83} Overlapping inflammatory pathways and genetic susceptibility may be potential biologic links underlying this association.\textsuperscript{78}

Discussion

The listed 41 recommendations cover the core aspects of treating SpA, including general principles, non-pharmacological treatment, pharmacological treatment, and special populations.
These recommendations are based on the adaptations of existing guidelines, particularly the ASAS/EULAR international recommendations, the current evidence and clinical experience of the members of the group, as well as the unique situation in Kuwait around differing patient profiles, local culture and approved therapeutic approaches. However, these are not designed to be full treatment guidelines and should be used appropriately to aid in clinical decision-making rather than guiding it.

**Author Contributions**

Yaser Ali was project supervisor and contributed to the conception and design of the work, the data analysis and interpretation, and drafting the article; Xenofon Baraliakos contributed to the design of the work and drafting the article. All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

**Funding**

Financial support was provided by Pfizer, Janssen and Novartis. Kuwait Association of Rheumatology (KAR) contributed to the consultation fees for each expert attending the meeting. Meeting support and organisation was provided by Pfizer and Synergy Medical Communications. In addition, Synergy Medical Communications provided editorial support and performed statistical analyses.

**Disclosure**

Yaser Ali, Fatemah Abutiban, Adel Alawadhi, Ali AlDei, Ahmad Alenizi, Hebah Alhajeri, Adeeba Al-Herz, Waleed Alkandari, Ahmad Dehrab, Eman Hasan, Sawson Hayat, Aqeel Ghanem and Khulood Saleh are members of the Kuwaiti Association for Rheumatology. Yaser Ali is employed by the Ministry of Health Kuwait and is a member of KAR. Xenofon Baraliakos has received honoraria from Abbvie, Janssen, Novartis and UCB. He is a Consultant Rheumatologist, Clinical Immunology and Allergy, FRPC, MsC, ABIM. Adel Alawadhi is a Professor and a Consultant Rheumatologist, MD, FRCP, FACP, FACR. Ali AlDei is a Rheumatology Senior Specialist, MD, FACP. Ahmad Alenizi is a Rheumatologist and the President of the Kuwait Medical Association Kuwait Association of Rheumatology, MD, FRCP, FACP, MACP. Hebah Alhajeri is a Senior Specialist in Rheumatology, MD, FRCP. Adeeba Al-Herz is a Consultant Rheumatologist and the President of Kuwait Association for Rheumatology, MD, FRPC, FACP. Waleed Alkandari is a Consultant of internal medicine and rheumatology, MD, FRCP. Fatemah Abutiban is a Consultant medicine and rheumatology, MD, FRCP. Ahmad Dehrab, MBBCh BAO, FACP. Eman Hasan is a Consultant Physician and Rheumatologist, MD, FRCP (UK). Sawson Hayat is a Consultant rheumatologist, MBBCh, MRCP (UK), KBIM, CESR (UK). Aqeel Ghanem is a Rheumatology Consultant and the Head of the Rheumatology Unit, MD, FRCPc. Khulood Saleh is a Consultant rheumatologist, FRCPc. Xenofon Baraliakos is an Associate Professor, MD. The authors report no conflicts of interest in this work.

**References**

1. Proft F, Poddubny D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. *Ther Adv Musculoskelet Dis*. 2018;10(5–6):129–139. doi:10.1177/1759720X18773726
2. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017;76(6):978–991. doi:10.1136/annrheumdis-2016-210770
3. van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. *Nat Rev Rheumatol.* 2015;11(2):110–118. doi:10.1038/nrrheum.2014.181
4. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*. 2009;68(6):777–783. doi:10.1136/ard.2009.108233
5. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis*. 2011;70(1):25–31. doi:10.1136/ard.2010.133645
6. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. *Ann Rheum Dis*. 2014;73(1):6–16. doi:10.1136/annrheumdis-2013-203419
7. Paramarta JE, Baeten D. Spondyloarthritis: from unifying concepts to improved treatment. *Rheumatology*. 2014;53(9):1547–1559. doi:10.1093/rheumatology/ket407
8. Pfizer. Press release. [Internet. Accessed August 13., 2018]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_provides_update_on_global_regulatory_approvals_and_launches_of_xeljanz_tofacitinib_citrate_for_the_treatment_of_rheumatoid_arthritis
9. Pfizer. Press release. [Internet]. 2018. Available from: https://press.pfizer.com/press-release/pfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor
10. European Medicines Agency. Summary of opinion. Xeljanz. Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/004214/WC500247974.pdf. Accessed July 2018
11. Xeljanz® (tofacitinib) Summary of Product Characteristics (Gulf Levant), Pfizer; 2019
12. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arth Rheum* 2016;68:282–298. doi:10.1002/art.39298
13. Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. *J Rheumatol*. 2015;42:654–664. doi:10.3899/jrheum.141000
14. Hammoudeh M, Abdulaziz S, Al-Awadhi A, et al. Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: an expert consensus. *J Int Med Res*. 2016;44(2):216–230. doi:10.1177/030006051611536
15. Al Enadi S, Hammoudeh M, Mounir M, et al. Ankylosing spondylitis: an update of the literature. *Ann Rheum Dis*. 2018;77(1):3–7. doi:10.1136/annrheumdis-2017-211734
16. Tofel S, Saleh N, Al-Awadhi A, et al. Easy accessibility of biologics and its impact on disease activity and quality of life in Kuwaiti patients with rheumatoid arthritis [abstract]. *Arthritis Rheumatol*. 2018;70(suppl):10.
17. Al Imadi S, Hammoudeh M, Mounir M, et al. An assessment of the current treatment landscape for rheumatology patients in Qatar: recognising unmet needs and moving towards solutions. *J Int Med Res*. 2017;45(2):733–743. doi:10.1177/03000605170611536
18. World population review. Available from: http://worldpopulationreview.com/countries/kuwait-population/. Accessed 13 August 2018.
19. Alawadhi M, Rutkowski R, Dudek A, Samborski W, Ali et al. Kuwait recommendations on vaccine use in people with inflammatory rheumatic disease. *Int J Rheumatol*. 2018;52:17461.
20. El-Enzeh A, Saleh K, Al-Awadhi A, et al. Easy accessibility of biologics and its impact on disease activity and quality of life in Kuwaiti patients with rheumatoid arthritis [abstract]. *Arthritis Rheumatol*. 2018;70(suppl):10.
21. Al Enadi S, Hammoudeh M, Mounir M, et al. Kuwait recommendations on vaccine use in people with inflammatory rheumatic disease. *Int J Rheumatol*. 2018;52:17461.
22. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. *Ann Rheum Dis*. 2011;70(1):47–53. doi:10.1136/ard.2008.104018
23. Smolen JS, Schölß M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Ann Rheum Dis*. 2018;77(1):3–17. doi:10.1136/annrheumdis-2017-211734
24. Bamberg T, van der Heijde D, van den Berg W, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. *Ann Rheum Dis*. 2014;73(8):1455–1461. doi:10.1136/annrheumdis-2014-205178
25. Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GERman Spondyloarthritis Inception Cohort. *Ann Rheum Dis*. 2016;75(12):2114–2118. doi:10.1136/annrheumdis-2016-209209
26. Pereira IA, Neves FS, Castro GRW. Extra-articular manifestations in spondyloarthritis are common and should be screened. *Rheumatol Curr Res*. 2012;2:3.
27. Gupta N, Agarwal A. Management of uveitis in spondyloarthropathy: current trends. *Perm J*. 2018;22:17–041.
77. Winthrop KL, Strand V, van der Heijde DM, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2016. *Clin Exp Rheumatol*. 2016;4(Suppl 98):69–76.

78. Gelfand J. Metabolic syndrome in patients with psoriatic disease. *J Rheumatol Suppl*. 2012;89:24–28. doi:10.3899/jrheum.120237

79. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. *Arch Dermatol*. 2011;147:1031–1039. doi:10.1001/archdermatol.2011.119

80. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. *J Invest Dermatol*. 2009;129(10):2411–2418. doi:10.1038/jid.2009.112

81. Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. *Br J Dermatol*. 2007;156(2):271–276. doi:10.1111/j.1365-2133.2006.07562.x

82. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. *Ann Rheum Dis*. 2009;68(7):1131–1135. doi:10.1136/ard.2008.094839

83. Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. *Metab Syndr Relat Disord*. 2010;8(4):331–334. doi:10.1089/met.2009.0124